These data suggest that LEC-derived chemokines promote the trafficking of MDSCs toward tumors and lymph nodes via CXCR2, and inhibition of CXCR2 increases the entry of NK cells, which may restore anti-cancer immunity in tumor microenvironments. The gene discussed is CXCR2; the disease is cancer.